Literature DB >> 24013749

Immunotherapy at large: Balancing tumor immunity and inflammatory pathology.

Glenn Dranoff1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24013749      PMCID: PMC4084937          DOI: 10.1038/nm.3335

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

Review 1.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 2.  Selectivity--key to chemotherapy: presidential address.

Authors:  G B Elion
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

Review 3.  Experimental mouse tumour models: what can be learnt about human cancer immunology?

Authors:  Glenn Dranoff
Journal:  Nat Rev Immunol       Date:  2011-12-02       Impact factor: 53.106

Review 4.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 7.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

Review 8.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 9.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.

Authors:  Padmanee Sharma; Klaus Wagner; Jedd D Wolchok; James P Allison
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  15 in total

1.  Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Authors:  H Kadara; M Choi; J Zhang; E R Parra; J Rodriguez-Canales; S G Gaffney; Z Zhao; C Behrens; J Fujimoto; C Chow; Y Yoo; N Kalhor; C Moran; D Rimm; S Swisher; D L Gibbons; J Heymach; E Kaftan; J P Townsend; T J Lynch; J Schlessinger; J Lee; R P Lifton; I I Wistuba; R S Herbst
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

Review 2.  Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.

Authors:  Enrico Franceschi; Santino Minichillo; Alba A Brandes
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

3.  Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Authors:  M Choi; H Kadara; J Zhang; E R Parra; J Rodriguez-Canales; S G Gaffney; Z Zhao; C Behrens; J Fujimoto; C Chow; K Kim; N Kalhor; C Moran; D Rimm; S Swisher; D L Gibbons; J Heymach; E Kaftan; J P Townsend; T J Lynch; J Schlessinger; J Lee; R P Lifton; R S Herbst; I I Wistuba
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

Review 4.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

Review 5.  Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Authors:  Matthias Preusser; Michael Lim; David A Hafler; David A Reardon; John H Sampson
Journal:  Nat Rev Neurol       Date:  2015-08-11       Impact factor: 42.937

Review 6.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Authors:  Deepak Mittal; Matthew M Gubin; Robert D Schreiber; Mark J Smyth
Journal:  Curr Opin Immunol       Date:  2014-02-14       Impact factor: 7.486

Review 7.  Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.

Authors:  Constantin N Baxevanis; Sonia A Perez
Journal:  Vaccines (Basel)       Date:  2015-07-30

Review 8.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

9.  Trial watch: Immunostimulatory cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-03       Impact factor: 8.110

Review 10.  T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity.

Authors:  Christopher V Carman; Roberta Martinelli
Journal:  Front Immunol       Date:  2015-11-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.